| Androgen deprivation therapy for prostate cancer N Sharifi, JL Gulley, WL Dahut Jama 294 (2), 238-244, 2005 | 1316 | 2005 |
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, ... Journal of Clinical Oncology 28 (7), 1099-1105, 2010 | 1206 | 2010 |
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 | 1142 | 1999 |
| Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis X Zhu, S Wu, WL Dahut, CR Parikh American journal of kidney diseases 49 (2), 186-193, 2007 | 801 | 2007 |
| Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer WL Dahut, JL Gulley, PM Arlen, Y Liu, KM Fedenko, SM Steinberg, ... Journal of clinical oncology 22 (13), 2532-2539, 2004 | 453 | 2004 |
| Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer JL Gulley, PM Arlen, A Bastian, S Morin, J Marte, P Beetham, KY Tsang, ... Clinical Cancer Research 11 (9), 3353-3362, 2005 | 431 | 2005 |
| A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer WD Figg, W Dahut, P Duray, M Hamilton, A Tompkins, SM Steinberg, ... Clinical Cancer Research 7 (7), 1888-1893, 2001 | 410 | 2001 |
| Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial RA Madan, M Mohebtash, PM Arlen, M Vergati, M Rauckhorst, ... The lancet oncology 13 (5), 501-508, 2012 | 367 | 2012 |
| A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. PM Arlen, JL Gulley, C Parker, L Skarupa, M Pazdur, D Panicali, ... Clinical cancer research: an official journal of the American Association …, 2006 | 361 | 2006 |
| Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer JL Gulley, PM Arlen, RA Madan, KY Tsang, MP Pazdur, L Skarupa, ... Cancer Immunology, Immunotherapy 59, 663-674, 2010 | 360 | 2010 |
| Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ... American journal of preventive medicine 20 (2), 16-66, 2001 | 335 | 2001 |
| The role of lineage plasticity in prostate cancer therapy resistance H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ... Clinical cancer research 25 (23), 6916-6924, 2019 | 312 | 2019 |
| Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel ER Gardner, WL Dahut, CD Scripture, J Jones, JB Aragon-Ching, N Desai, ... Clinical Cancer Research 14 (13), 4200-4205, 2008 | 280 | 2008 |
| Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy WD Stein, JL Gulley, J Schlom, RA Madan, W Dahut, WD Figg, Y Ning, ... Clinical Cancer Research 17 (4), 907-917, 2011 | 275 | 2011 |
| Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019 VN Giri, KE Knudsen, WK Kelly, HH Cheng, KA Cooney, MS Cookson, ... Journal of Clinical Oncology 38 (24), 2798-2811, 2020 | 271 | 2020 |
| Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer J Gulley, AP Chen, W Dahut, PM Arlen, A Bastian, SM Steinberg, K Tsang, ... The Prostate 53 (2), 109-117, 2002 | 269 | 2002 |
| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations F Karzai, D VanderWeele, RA Madan, H Owens, LM Cordes, A Hankin, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 267 | 2018 |
| Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma JL Gulley, PM Arlen, KY Tsang, J Yokokawa, C Palena, DJ Poole, ... Clinical Cancer Research 14 (10), 3060-3069, 2008 | 256 | 2008 |
| A phase I trial of depsipeptide (FR901228) in patients with advanced cancer JL Marshall, N Rizvi, J Kauh, W Dahut, M Figuera, MH Kang, WD Figg, ... Journal of Experimental Therapeutics and Oncology 2 (6), 325-332, 2002 | 256 | 2002 |
| Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time PM Arlen, F Bianco, WL Dahut, A D'Amico, WD Figg, SJ Freedland, ... The Journal of urology 179 (6), 2181-2186, 2008 | 242 | 2008 |
